Professor Richard J Ross
MD, FRCP
Clinical Medicine, School of Medicine and Population Health
Professor of Endocrinology
r.j.ross@sheffield.ac.uk
+44 114 215 9089
+44 114 215 9089
+44 114 215 9004
(Secretary: Lindsey Crowson)
Office: EU14, The Medical School
Full contact details
Professor Richard J Ross
Clinical Medicine, School of Medicine and Population Health
Office: EU14
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Clinical Medicine, School of Medicine and Population Health
Office: EU14
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries, please contact - iicd-om-operational@sheffield.ac.uk
I trained in medicine at The Royal London Hospital (1974-1979) and in Endocrinology at St Bartholomew´s Hospital, London (1983-1988). I was appointed to Sheffield University in 1995 and am Head of the Unit of Diabetes and Endocrinology.
I previously served on the Medical School Council as Head of Section for Endocrinology and Reproduction (2005-2008) and as Director of Sheffield Health Innovation Centre subsequently Sheffield Healthcare Gateway (2008-2018).
My research and clinical interests are in pituitary and adrenal disease, transition endocrinology and the late effects of cancer therapy.
I am a founding Director of two university spin-out companies; Asterion Ltd and Diurnal Plc.
I served on the editorial boards of: Clinical Endocrinology (1996-2000), Growth & Growth Factors (1986-2006), Hormones (2004-), and J Clin Endocrinol Metab (2010-2014).
I am a council member for the Society of Endocrinology (1999-2002), Editor Endocrinologist (2001-2004), Chair of CaHASE (2002-2015), member of the Bioscientifica Board (2006-2010), Society for Endocrinology Public Engagement Committee (2008-2011) and Nominations Committee (2010-2012).
Executive Committee of the European Society of Endocrinology (2011-2015), Treasurer of the European Society of Endocrinology (2013-2015), and The Growth Hormone Research Society Council (2011-2016).
- Research interests
-
The focus of both my clinical and basic research is on optimising endocrine hormone replacement. My group have identified and characterised uncommon mutations in the growth hormone receptor which have led to fundamental observations on the mechanism by which the growth hormone receptor signals through a pre-formed dimer.
This work led to a greater understanding of the regulation of growth hormone secretion and the group have developed a long acting form of growth hormone and this work was published in Nature Medicine in 2007. The group are now actively developing a long acting growth hormone antagonist.
The Clinical Research Programme has been investigating different regimens for replacing cortisol, testosterone and oestrogen in hypopituitary, hypogonadal and adrenal insufficient patients.
The group have designed modified release forms of hydrocortisone, including Infacort for the treatment of neonates and children with adrenal insufficiency and Chronocort, to replicate the normal circadian rhythm of cortisol.
Infacort received a Market Authorisation from EMA in 2018 and is being marketed under the trade name Alkindi and Chronocort is currently completing phase 3 clinical trials in patients with congenital adrenal hyperplasia. Other work has examined the incidence of hypogonadism in cancer survivors and replacing testosterone in young male cancer survivors.
The Endocrine Unit consists of 6 Consultant Endocrinologists and runs a number of unique and innovative specialist clinics in the Health Care Trust including: Pituitary Clinic, Transition Clinic for Paediatric Endocrinology, Late Effects Clinic for Cancer survivors, Joint Surgical Endocrine Clinics, Obesity Clinic, Genetic Endocrine Clinic and a Pituitary Multidisciplinary Team.
Publications and Patents: 286 publications during career, Scopus h-index of 46. 35 patents granted from 7 independent patent families.
Current projects
- Improving the care of patients with congenital adrenal hyperplasia and adrenal insufficiency
- Development of long-acting biologicals including growth hormone antagonists for the treatment of acromegaly
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Home waking salivary cortisone to screen for adrenal insufficiency. NEJM Evidence, 2(2).
- Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm. Drug Delivery and Translational Research, 13(1), 1-8.
- Main salivary steroid collection in children under conditions replicating home sampling. Journal of Clinical Endocrinology and Metabolism, 107(11), 3128-3136.
- Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet Healthy Longevity, 3(6), e381-e393.
- Development of a hypoparathyroid male rodent model for testing delayed-clearance PTH molecules. Endocrinology, 163(2).
- Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. European Journal of Endocrinology, 186(1), R1-R14.
- An oral lipidic native testosterone formulation that is absorbed independent of food. European Journal of Endocrinology, 185(5), 607-615.
- Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency. European Journal of Pharmaceutical Sciences, 165.
- Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study).. Pituitary, 24(5), 768-777.
- Hydrocortisone granules in capsules for opening (Alkindi) as replacement therapy in pediatric patients with adrenal insufficiency. Expert Opinion on Orphan Drugs, 9(3), 67-76.
- A prospective study of children aged 0–8 years with CAH and adrenal insufficiency treated with hydrocortisone granules. The Journal of Clinical Endocrinology & Metabolism, 106(3), e1433-e1440. View this article in WRRO
- Modified-release hydrocortisone in congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism. View this article in WRRO
- Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLOS Medicine, 16(11), ---. View this article in WRRO
- Salivary cortisone to estimate cortisol exposure and sampling frequency required based on serum cortisol measurements. Journal of Clinical Endocrinology and Metabolism. View this article in WRRO
- Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clinical Endocrinology, 88(1), 21-29. View this article in WRRO
- A long-acting GH receptor antagonist through fusion to GH binding protein.. Scientific Reports, 6. View this article in WRRO
- Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1469-1477. View this article in WRRO
- A Phase 2 Study of Chronocort, a Modified-Release Formulation of Hydrocortisone, in the Treatment of Adults With Classic Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism, 100(3), 1137-1145.
- Development and Testing in Healthy Adults of Oral Hydrocortisone Granules With Taste Masking for the Treatment of Neonates and Infants With Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism, 100(4), 1681-1688.
- An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.. Clinical Endocrinology, 80(4), 554-561. View this article in WRRO
- Treatment and health outcomes in adults with congenital adrenal hyperplasia.. Nat Rev Endocrinol, 10(2), 115-124.
- Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody.. Structure, 20(3), 487-497.
- Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients.. J Clin Endocrinol Metab, 95(11), 5110-5121.
- Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions.. Clin Sci (Lond), 119(11), 483-491.
- Modified-release hydrocortisone to provide circadian cortisol profiles.. J Clin Endocrinol Metab, 94(5), 1548-1554. View this article in WRRO
- Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels.. J Clin Endocrinol Metab, 93(6), 2300-2306.
- Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study.. J Clin Endocrinol Metab, 92(9), 3476-3482.
- A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist.. Nat Med, 13(9), 1108-1113.
- Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.. Clin Endocrinol (Oxf), 61(3), 367-375.
- Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization.. J Clin Endocrinol Metab, 89(9), 4532-4537.
- Leptin indirectly activates human neutrophils via induction of TNF-alpha.. J Immunol, 172(3), 1809-1814. View this article in WRRO
- Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. P Natl Acad Sci USA, 100(3), 1016-1021. View this article in WRRO
- Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet, 31(4), 379-384.
- High-dose leptin activates human leukocytes via receptor expression on monocytes.. J Immunol, 167(8), 4593-4599. View this article in WRRO
- Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.. J Clin Endocrinol Metab, 86(4), 1716-1723.
- A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet, 16(1), 13-14.
- A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein.. Mol Endocrinol, 11(3), 265-273.
- Diabetes-mellitus associated with a pathogenic point mutation in mitochondrial-DNA. Lancet, 340.
- Treatment of Growth-Hormone Deficiency with Growth-Hormone Releasing Hormone. Lancet, 1.
- Improved biochemical control with modified-release hydrocortisone overturns the impaired fludrocortisone effect in salt-wasting CAH patients. Endocrine Abstracts.
- Adrenal insufficiency. Nature Reviews Disease Primers, 7(1).
All publications
Journal articles
- Model-Informed target morning 17α-hydroxyprogesterone concentrations in dried blood spots for pediatric congenital adrenal hyperplasia patients. Pharmaceuticals, 16(3).
- Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia. Endocrine, 80, 630-638.
- Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach. Frontiers in Pharmacology, 13.
- Home waking salivary cortisone to screen for adrenal insufficiency. NEJM Evidence, 2(2).
- Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm. Drug Delivery and Translational Research, 13(1), 1-8.
- Main salivary steroid collection in children under conditions replicating home sampling. Journal of Clinical Endocrinology and Metabolism, 107(11), 3128-3136.
- Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet Healthy Longevity, 3(6), e381-e393.
- Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.. Bone Marrow Transplant.
- Development of a hypoparathyroid male rodent model for testing delayed-clearance PTH molecules. Endocrinology, 163(2).
- Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. European Journal of Endocrinology, 186(1), R1-R14.
- An oral lipidic native testosterone formulation that is absorbed independent of food. European Journal of Endocrinology, 185(5), 607-615.
- Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplantation and Cellular Therapy.
- Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency. European Journal of Pharmaceutical Sciences, 165.
- Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study).. Pituitary, 24(5), 768-777.
- Medical Treatment Achieves Similar Quality of Life to Surgically Treated Acromegaly Patients in Remission: The QuaLAT Study. Journal of the Endocrine Society, 5(Suppl 1), a522-a522.
- Hydrocortisone granules in capsules for opening (Alkindi) as replacement therapy in pediatric patients with adrenal insufficiency. Expert Opinion on Orphan Drugs, 9(3), 67-76.
- A prospective study of children aged 0–8 years with CAH and adrenal insufficiency treated with hydrocortisone granules. The Journal of Clinical Endocrinology & Metabolism, 106(3), e1433-e1440. View this article in WRRO
- Modified-release hydrocortisone in congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism. View this article in WRRO
- International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registry. European Journal of Endocrinology. View this article in WRRO
- Development of a large adrenal myelolipoma in the context of long-term elevated ACTH. BMJ Case Reports, 14(1), e240493-e240493.
- Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism, 106(1), e192-e203.
- Response to ‘Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia’. European Journal of Endocrinology, 183(6), L29-L30.
- Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. Journal of Clinical Endocrinology and Metabolism, 105(8), 2692-2703. View this article in WRRO
- Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children. European Journal of Endocrinology, 183(4), 357-368.
- MON-170 Real World Estimates of Adrenal Insufficiency Related Adverse Events in Children with Congenital Adrenal Hyperplasia: On Behalf of the I-CAH Consortium. Journal of the Endocrine Society, 4(Supplement_1).
- OR25-02 A phase 3 study of a modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia. Journal of the Endocrine Society, 4(Supplement_1). View this article in WRRO
- SAT-408 Bioactivity of Long Acting PTH Fusion Molecules Tested in a Novel Non-Surgical Animal Model of Hypoparathyroidism. Journal of the Endocrine Society, 4(Supplement_1). View this article in WRRO
- SAT-396 A Non-Surgical Animal Model of Hypoparathyroidism for Testing PTH Analogues. Journal of the Endocrine Society, 4(Supplement_1). View this article in WRRO
- SUN-197 Giant Adrenal Myelolipoma Associated with Prolonged ACTH Elevation in a Patient with Congenital Adrenal Hyperplasia (CAH). Journal of the Endocrine Society, 4(Supplement_1).
- SAT-LB6 First Human Trial of an Oral Native Testosterone Shows Physiological Levels of Testosterone and Dht in Both Fasted and Fed State in Hypogonadal Men. Journal of the Endocrine Society, 4(Supplement_1).
- Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo. Journal of Endocrinology, 245(2), 207-218. View this article in WRRO
- Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism, 105(1), 314-326.
- Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLOS Medicine, 16(11), ---. View this article in WRRO
- Tuberculosis as a differential for bilateral adrenal masses in the UK. BMJ Case Reports, 12(5), e228532-e228532.
- The circadian rhythm of corticosteroid‐binding globulin has little impact on cortisol exposure after hydrocortisone dosing. Clinical Endocrinology. View this article in WRRO
- Hydrocortisone Granules are Bioequivalent When Sprinkled onto Food or Given Directly on the Tongue. Journal of the Endocrine Society. View this article in WRRO
- Accuracy of hydrocortisone dose administration via nasogastric tube. Clinical Endocrinology. View this article in WRRO
- Salivary cortisone to estimate cortisol exposure and sampling frequency required based on serum cortisol measurements. Journal of Clinical Endocrinology and Metabolism. View this article in WRRO
- Adrenal insufficiency in young children : a mixed methods study of parents’ experiences. Journal of Genetic Counseling, 27(6), 1447-1458. View this article in WRRO
- Use of salivary cortisol and cortisone in the high and low dose synacthen test. Clinical Endocrinology, 88(6), 772-778. View this article in WRRO
- International survey on high- and low-dose synacthen test and assessment of accuracy in preparing low-dose synacthen. Clinical Endocrinology, 88(5), 744-751. View this article in WRRO
- Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. Clinical Pharmacokinetics, 57, 515-527. View this article in WRRO
- Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia. European Journal of Endocrinology, 178(4), 309-320. View this article in WRRO
- Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme). Expert Review of Endocrinology & Metabolism, 13(3), 119-124. View this article in WRRO
- Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 7(3), r126-r134. View this article in WRRO
- Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clinical Endocrinology, 88(1), 21-29. View this article in WRRO
- Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. Journal of Bioequivalence & Bioavailability, 10(1), 1-3. View this article in WRRO
- Human studies on hypothalamo-pituitary-adrenal (HPA) axis. Best Practice & Research Clinical Endocrinology & Metabolism, 31(5), 459-473.
- Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly. Endocrinology, Diabetes & Metabolism Case Reports. View this article in WRRO
- Salivary cortisol and cortisone in the clinical setting. Current Opinion in Endocrinology & Diabetes and Obesity, 24(3), 161-168.
- Quality of compounded hydrocortisone capsules used in the treatment of children. European Journal of Endocrinology. View this article in WRRO
- Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia.. Eur J Endocrinol. View this article in WRRO
- Androgens correlate with increased erythropoiesis in women with congenital adrenal hyperplasia. Clinical Endocrinology, 86(1), 19-25. View this article in WRRO
- Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism, jc.2016-2855-jc.2016-2855. View this article in WRRO
- A long-acting GH receptor antagonist through fusion to GH binding protein.. Scientific Reports, 6. View this article in WRRO
- A model for measuring the health burden of classic congenital adrenal hyperplasia in adults. Clinical Endocrinology, 85(3), 361-398. View this article in WRRO
- Is physiological glucocorticoid replacement important in children?. Arch Dis Child. View this article in WRRO
- Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. European Journal of Endocrinology, 174, C1-C8. View this article in WRRO
- Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1469-1477. View this article in WRRO
- GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. European Journal of Endocrinology, 174(2), P1-P9. View this article in WRRO
- Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Clinical Endocrinology, 84(2), 296-304.
- Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers. European Journal of Endocrinology, 173(6), 727-737. View this article in WRRO
- Testosterone replacement in young male cancer survivors (TRYMS) - pragmatic adaptation of trial design for a trial struggling with recruitment. Trials, 16(S2). View this article in WRRO
- The Burden of Illness of Congenital Adrenal Hyperplasia In The United Kingdom: A Retrospective, Observational Study. Value in Health, 18(7), A749-A749.
- Status of long-acting-growth hormone preparations — 2015. Growth Hormone & IGF Research, 25(5), 201-206.
- A Phase 2 Study of Chronocort, a Modified-Release Formulation of Hydrocortisone, in the Treatment of Adults With Classic Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism, 100(3), 1137-1145.
- Development and Testing in Healthy Adults of Oral Hydrocortisone Granules With Taste Masking for the Treatment of Neonates and Infants With Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism, 100(4), 1681-1688.
- Optimal glucocorticoid replacement in adrenal insufficiency. Best Practice & Research Clinical Endocrinology & Metabolism, 29(1), 3-15.
- TRYMS: the ethical and practical considerations of a double-blind placebo controlled randomised clinical trial. Trials, 16(S2). View this article in WRRO
- Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas. The Journal of Clinical Endocrinology & Metabolism, 99(12), 4462-4470.
- Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits. Disease Models & Mechanisms, 7(11), 1263-1273. View this article in WRRO
- Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE).. J Clin Endocrinol Metab, 99(8), E1547-E1555.
- Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.. Bone Marrow Transplant.
- CaHASE: a Specialist Society Led Academic Collaboration to improve the management of CAH.. Clin Endocrinol (Oxf), 81(3), 334-335.
- Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma.. Bone Marrow Transplant, 49(7), 907-912.
- An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.. Clinical Endocrinology, 80(4), 554-561. View this article in WRRO
- Treatment and health outcomes in adults with congenital adrenal hyperplasia.. Nat Rev Endocrinol, 10(2), 115-124.
- Developing long-acting growth hormone formulations.. Clin Endocrinol (Oxf), 79(3), 305-309.
- Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma.. J Clin Endocrinol Metab, 98(6), 2383-2391.
- Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study.. PLoS One, 8(4), e60984-e60984. View this article in WRRO
- Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). EUROPEAN JOURNAL OF ENDOCRINOLOGY, 168(6), 887-893. View this article in WRRO
- Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clinical Endocrinology, 78(2), 197-203.
- Genotype-phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE) cohort.. J Clin Endocrinol Metab, 98(2), E346-E354.
- What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012?. Clin Endocrinol (Oxf), 78(5), 659-664.
- Expression of a glycosylphosphatidylinositol-anchored ligand, growth hormone, blocks receptor signalling.. Biosci Rep, 32(6), 653-660. View this article in WRRO
- Out Through the Eye: When Prolactinomas Go Bad. Journal of Neurological Surgery Part B: Skull Base, 73(S 02).
- Structure of the human obesity receptor leptin-binding domain reveals the mechanism of leptin antagonism by a monoclonal antibody.. Structure, 20(3), 487-497.
- Reconstitution Graves' disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis.. QJM, 105(4), 369-371.
- Transnasal trans-sphenoidal endoscopic repair of CSF leak secondary to invasive pituitary tumours using a nasoseptal flap.. Pituitary, 14(2), 163-167.
- Reduced appetite and body mass index with delayed puberty in a mother and son: association with a rare novel sequence variant in the leptin gene.. Eur J Endocrinol, 164(4), 521-527.
- Optimal glucocorticoid therapy.. Endocr Dev, 20, 173-180.
- Restricted leptin antagonism as a therapeutic approach to treatment of autoimmune diseases. Hormones, 10(1), 16-26.
- Assessing adrenal status in patients before and immediately after coronary artery bypass graft surgery.. Eur J Endocrinol, 164(3), 413-419.
- Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients.. J Clin Endocrinol Metab, 95(11), 5110-5121.
- Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions.. Clin Sci (Lond), 119(11), 483-491.
- Increased fat mass may be protective of bone mass in young male cancer survivors. Bone, 47, S189-S190.
- A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (ChronocortTM) vs. conventional hydrocortisone (CortefTM) in the treatment of congenital adrenal hyperplasia. Clinical Endocrinology, 72(4), 441-447.
- Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study.. Cancer, 116(6), 1592-1601.
- Current health status of adult patients with congenital adrenal hyperplasia and the potential for new therapies. Endocr J, 57, S307-S307.
- Survivors of childhood cancer Integrated follow-up is needed. Brit Med J, 340.
- Growth Hormone (GH) Insensitivity Syndrome due to a GH Receptor Truncated after Box1, Resulting in Isolated Failure of STAT 5 Signal Transduction (vol 89, pg 1259, 2004). JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 94(7), 2674-2674.
- Cross-sectional analysis of testosterone therapies in hypopituitary men on stable pituitary hormone replacement.. Clin Endocrinol (Oxf), 70(6), 907-913.
- Follow-up care after childhood cancer: survivors' expectations and preferences for care.. Eur J Cancer, 45(9), 1616-1623.
- Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy.. Eur J Endocrinol, 160(5), 719-729.
- Modified-release hydrocortisone to provide circadian cortisol profiles.. J Clin Endocrinol Metab, 94(5), 1548-1554. View this article in WRRO
- Novel strategies for hydrocortisone replacement.. Best Pract Res Clin Endocrinol Metab, 23(2), 221-232.
- Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after box1, resulting in isolated failure of STAT 5 signal transduction (Journal of Clinical Endocrinology and Metabolism (2004) 89 (1259-1266)). Journal of Clinical Endocrinology and Metabolism, 94(7), 2674.
- Ovarian failure following cancer treatment: current management and quality of life.. Hum Reprod, 23(11), 2506-2512.
- Efficacy of current growth hormone treatments and future therapies.. J Endocrinol Invest, 31(9 Suppl), 48-51.
- Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels.. J Clin Endocrinol Metab, 93(6), 2300-2306.
- Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers.. Clin Endocrinol (Oxf), 68(1), 130-135.
- Women gain weight and fat mass despite lipectomy at abdominoplasty and breast reduction. European Journal of Endocrinology, 158(3), 349-352.
- Wide variation in surgical outcomes for acromegaly in the UK. Clinical Endocrinology, 68(1), 136-142.
- Reassurance following breast screening recall for female survivors of Hodgkin's lymphoma.. Breast, 16(6), 590-596.
- Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study.. J Clin Endocrinol Metab, 92(9), 3476-3482.
- Doses and steroids to be used in primary and central hypoadrenalism.. Ann Endocrinol (Paris), 68(4), 265-267.
- A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist.. Nat Med, 13(9), 1108-1113.
- Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.. J Clin Endocrinol Metab, 92(5), 1758-1763.
- Combining growth hormone releasing hormone-arginine and synacthen testing diminishes the cortisol response.. J Clin Endocrinol Metab, 92(3), 853-856.
- Membrane reinsertion of a myristoyl-peptidyl anchored extracellular domain growth hormone receptor.. Endocrinology, 148(2), 824-830.
- Spin doctors: meeting clinical need and biological product development. J Pharm Pharmacol, 59, A65-A65.
- Follow-up after childhood cancer: evaluation of a three-level model.. Eur J Cancer, 42(18), 3186-3190.
- Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. Journal of Clinical Investigation, 116(9), 2442-2455.
- Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.. Clin Endocrinol (Oxf), 65(1), 45-50.
- Predictors of clinic satisfaction among adult survivors of childhood cancer.. Eur J Cancer, 42(10), 1421-1427.
- Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.. Int J Androl, 29(3), 381-391.
- Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation.. J Immunol Methods, 312(1-2), 190-200.
- High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening.. Br J Cancer, 94(4), 469-472. View this article in WRRO
- A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signaling.. J Endocrinol, 188(2), 251-261.
- A mutant signal transducer and activator of transcription 5b, associated with growth hormone insensitivity and insulin-like growth factor-I deficiency, cannot function as a signal transducer or transcription factor. Journal of Clinical Endocrinology and Metabolism, 91(4), 1526-1534.
- Hypopituitary patients prefer a touch-screen to paper quality of life questionnaire.. Growth Horm IGF Res, 15(6), 384-387.
- Follow-up care for childhood cancer survivors: a focus group analysis.. Eur J Cancer, 41(18), 2882-2886.
- Estrogen replacement in women of fertile years with hypopituitarism.. J Clin Endocrinol Metab, 90(11), 5964-5969.
- Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.. Eur J Endocrinol, 152(4), 569-574.
- Timing and type of glucocorticoid replacement in adult congenital adrenal hyperplasia.. Horm Res, 64 Suppl 2, 67-70.
- Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. Journal of Clinical Endocrinology and Metabolism, 90(2), 1055-1060.
- Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.. Clin Endocrinol (Oxf), 61(3), 367-375.
- Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization.. J Clin Endocrinol Metab, 89(9), 4532-4537.
- A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.. J Clin Endocrinol Metab, 89(5), 2039-2043.
- Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocr Metab, 89(4), 1684-1693.
- Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT 5 signal transduction.. J Clin Endocrinol Metab, 89(3), 1259-1266.
- Leptin indirectly activates human neutrophils via induction of TNF-alpha.. J Immunol, 172(3), 1809-1814. View this article in WRRO
- Patients with chronic pain and abnormal pituitary function require investigation.. Lancet, 361(9376), 2203-2204.
- Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. P Natl Acad Sci USA, 100(3), 1016-1021. View this article in WRRO
- Pegvisomant: structure and function.. J Mol Endocrinol, 29(1), 11-14.
- Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet, 31(4), 379-384.
- Optimisation of Hydrocortisone Replacement Therapy. Clinical Science, 103(s47), 24P-24P.
- Human growth hormone replacement in adult hypopituitary patients: Long-term effects on body composition and lipid status - 3-year results from the HypoCCS database. J Clin Endocr Metab, 87(4), 1600-1606.
- Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?. Journal of Clinical Endocrinology and Metabolism, 87(2), 447-485.
- Serum leptin and leptin binding activity in children and adolescents with hypothalamic dysfunction. Journal of Pediatric Endocrinology and Metabolism, 15(7), 963-971.
- An exonic splicing enhancer in human IGF-I pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor.. Endocrinology, 143(1), 146-154.
- High-dose leptin activates human leukocytes via receptor expression on monocytes.. J Immunol, 167(8), 4593-4599. View this article in WRRO
- Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors.. Endocrinology, 142(10), 4389-4393.
- Is there a medical need to explore the clinical use of insulin-like growth factor I?. Growth Horm IGF Res, 11 Suppl A, S65-S69.
- Differential expression of suppressors of cytokine signalling genes in response to nutrition and growth hormone in the septic rat.. J Endocrinol, 169(2), 409-415.
- Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.. J Clin Endocrinol Metab, 86(4), 1716-1723.
- A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women.. Hum Genet, 108(3), 233-236.
- In rats with sepsis, the acute fall in IGF-I is associated with an increase in circulating growth hormone-binding protein levels. Intensive Care Medicine, 26(10), 1547-1552.
- High-dose growth hormone does not affect proinflammatory cytokine (tumor necrosis factor-alpha, interleukin-6, and interferon-gamma) release from activated peripheral blood mononuclear cells or after minimal to moderate surgical stress.. J Clin Endocrinol Metab, 85(9), 3383-3390.
- GH, IGF-I and binding proteins in altered nutritional states.. Int J Obes Relat Metab Disord, 24 Suppl 2, S92-S95.
- Stimulation of endogenous GH and interleukin-6 receptors selectively activates different Jaks and Stats, with a Stat5 specific synergistic effect of dexamethasone.. J Endocrinol, 165(2), 301-311.
- Inflammatory cytokines and acquired growth hormone resistance.. Growth Horm IGF Res, 10 Suppl B, S9-14.
- Association of elevated insulin-like growth factor binding protein-1 with insulin resistance in hyperthyroidism.. Clin Endocrinol (Oxf), 52(2), 187-195.
- Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues. Journal of Clinical Endocrinology and Metabolism, 85(8), 2865-2871.
- Serum Leptin Levels during Pregnancy: Significance of Pregnancy Outcome and Smoking Status. Clinical Science, 97(s41), 6P-6P.
- Leptin binding activity changes with age: the link between leptin and puberty.. J Clin Endocrinol Metab, 84(7), 2336-2341.
- Effects of growth hormone replacement on physical performance and body composition in GH deficient adults.. Clin Endocrinol (Oxf), 51(1), 53-60.
- The GH receptor and GH insensitivity.. Growth Horm IGF Res, 9 Suppl B, 42-45.
- Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.. J Endocrinol Invest, 22(6), 409-418.
- The GH receptor and GH insensitivity - Summary of discussion following presentation. Growth Horm IGF Res, 9, 45-46.
- Expression of leptin receptor isoforms in the human endometrium. Hum Reprod, 14, 370-370.
- Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling.. J Biol Chem, 274(21), 14791-14798.
- The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis.. J Clin Endocrinol Metab, 84(4), 1220-1225.
- Lack of association between thyroid and adrenal nodules: a histological study.. J Endocrinol Invest, 22(4), 262-265.
- The growth hormone IGF-I axis in dilated cardiomyopathy.. Clin Endocrinol (Oxf), 50(4), 415-416.
- The growth hormone IGF-I axis in dilated cardiomyopathy. Clin Endocrinol, 50(4), 415-416.
- The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis. J Clin Endocr Metab, 84(4), 1220-1225.
- Truncated growth hormone receptor isoforms.. Acta Paediatr Suppl, 88(428), 164-166.
- Serum leptin levels during the menstrual cycle of healthy fertile women.. Br J Biomed Sci, 56(1), 16-19.
- Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.. Journal of Endocrinological Investigation 1999 22:409-418.
- Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST).. Clin Endocrinol (Oxf), 49(6), 773-778.
- Endocrine investigation: Cushing's syndrome.. Clin Endocrinol (Oxf), 49(2), 153-155.
- Acquired growth hormone resistance in adults.. Baillieres Clin Endocrinol Metab, 12(2), 315-329.
- Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors.. J Clin Endocrinol Metab, 83(7), 2532-2538.
- Serum collagen crosslinks as markers of bone turn-over during GH replacement therapy in growth hormone deficient adults. Clin Endocrinol, 48(4), 455-462.
- Association of GLN223ARG polymorphism in the leptin receptor gene with serum leptin levels and BMI in postmenopausal Caucasian women. Eur J Hum Genet, 6, 107-107.
- Definition of growth hormone resistance. Journal of Endocrinological Investigation, 21(8 SUPPL.), 2-5.
- The role of IGFs in catabolism.. Baillieres Clin Endocrinol Metab, 11(4), 679-697.
- Growth hormone therapy in patients with cirrhosis: A pilot study of efficacy and safety. Gastroenterology, 113(5), 1617-1622.
- Growth hormone insensitivity: Genetic and acquired. Endocrinol Metab, 4, 49-49.
- A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet, 16(1), 13-14.
- A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein.. Mol Endocrinol, 11(3), 265-273.
- A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol, 11(3), 265-273.
- Administration of human recombinant insulin-like growth factor-I in critically ill patients. Critical Care Medicine, 25(8), 1352-1361.
- The use of growth hormone and insulin-like growth factor-I in catabolic states. Journal of Pediatric Endocrinology and Metabolism, 10(SUPPL. 1), 131-136.
- Growth hormone therapy for protein catabolism.. QJM, 89(11), 813-819.
- Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound.. Pediatr Radiol, 26(11), 794-799.
- Reduction in circulating IGF-I and hepatic IGF-I mRNA levels after caecal ligation and puncture are associated with differential regulation of hepatic IGF-binding protein-1, -2 and -3 mRNA levels.. J Endocrinol, 151(2), 287-292.
- Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease.. Crit Care Med, 24(9), 1460-1466.
- Acquired growth hormone resistance in catabolic states.. Baillieres Clin Endocrinol Metab, 10(3), 411-419.
- Growth hormone treatment in hypopituitary GH deficient adults reduces circulating cortisol levels during hydrocortisone replacement therapy.. Clin Endocrinol (Oxf), 45(1), 33-37.
- Expression of IGF-I and IGF-binding protein genes in cirrhotic liver.. J Endocrinol, 149(2), 209-216.
- Interpretation of cortisol response to synacthen. Ann Clin Biochem, 33, 175-176.
- Relative value of computed tomography scanning and venous sampling in establishing the cause of primary hyperaldosteronism.. Eur J Endocrinol, 134(3), 308-313.
- The endocrinology of the critically ill. Current Opinion in Endocrinology and Diabetes, 3(2), 138-145.
- The differential regulation of the circulating levels of the insulin-like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery. Clinical Endocrinology, 44(1), 91-101.
- Regulation of hepatic mRNA levels for the growth hormone receptor in rats with altered thyroid status.. Growth Regul, 5(4), 199-202.
- Acquired growth hormone resistance.. Eur J Endocrinol, 132(6), 655-660.
- Diagnosis and selective cure of Cushing's disease during pregnancy by transsphenoidal surgery.. Eur J Endocrinol, 132(6), 722-726.
- An alternatively spliced human insulin-like growth factor-I transcript with hepatic tissue expression that diverts away from the mitogenic IBE1 peptide.. Endocrinology, 136(5), 1939-1944.
- Growth-hormone, insulin-like growth-factor-I, and insulin-like growth-factor binding-proteins-! and binding-proteins-3 in chronic liver-disease. Hepatology, 21.
- Primary hyperaldosteronism due to an adrenal adenoma in a 14-year-old boy.. Postgrad Med J, 71(832), 104-106.
- Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.. Clin Endocrinol (Oxf), 42(1), 17-21.
- Maternally inherited diabetes and deafness is a distinct subtype of diabetes and associates with a single-point mutation in the mitochondrial TRNA(LEU(UUR) gene. Diabetes, 43.
- Expression of IGFBP-1 in normal and cirrhotic human livers.. J Endocrinol, 141(2), 377-382.
- Changes in hepatic insulin-like growth factor-binding protein-1, protein-2 and protein-3 messenger-RNA levels in rats with altered thyroid status. Journal of Endocrinology, 140.
- Growth hormone replacement in adults: what dose?. Clin Endocrinol (Oxf), 39(4), 401-402.
- Insulin-like growth-factor binding-proteins (IGFBPS), The growth-hormone (GH) - insulin-like growth factor - I (IGF-1) axis - age and nutritional indexes in cirrhosis. Hepatology, 18.
- Effects of hypothyroidism and hyperthyroidism on insulin-like growth-factors (IGFS) and growth hormone-binding and IGF-binding proteins. Journal of Clinical Endocrinology & Metabolism, 76.
- The effects of dexamethasone treatment on immunoreactive and bioactive insulin-like growth-factors (IGFS) and IGF-binding proteins in normal-male volunteers. Journal of Endocrinology, 136.
- Acquired growth hormone resistance in patients with hypercatabolism.. Horm Res, 40(1-3), 87-91.
- The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill.. Intensive Care Med, 19 Suppl 2, S54-S57.
- Influence of thyroid hormones on the GH-IGF-I axis. Trends in Endocrinology and Metabolism, 4(5), 169-173.
- Diabetes-mellitus associated with a pathogenic point mutation in mitochondrial-DNA. Lancet, 340.
- Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clinical Endocrinology, 37(6), 542-551.
- Avoiding autocannibalism.. BMJ, 303(6811), 1147-1148.
- Life-threatening hypercalcaemia in association with Addisonian crisis. [published erratum appears in Postgrad Med J 1991 Nov;67(793):67]. Postgraduate Medical Journal, 67, 770-772..
- Levels of GH binding-activity, IGFBP-1, insulin, blood-glucose and cortisol in intensive-care patients. Clinical Endocrinology, 35.
- The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness.. J Endocrinol, 130(3), 469-473.
- Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.. Clin Endocrinol (Oxf), 34(5), 407-411.
- Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion.. Clin Endocrinol (Oxf), 33(2), 239-248.
- Pyridostigmine, an acetylcholinesterase inhibitor, stimulates growth-hormone release, but has no effect on basal thyrotropin or adrenocorticotropin levels, or the thyrotropin response to thyrotropin-releasing-hormone. Journal of Neuroendocrinology, 2.
- Growth Hormone Secretion: Its Regulation and the Influence of Nutritional Factors. Nutrition Research Reviews, 3(1), 143-162.
- Opioids stimulate Growth-Hormone (GH) release in man independently of GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 69.
- Massive prolactinoma with galactorrhoea in a prepubertal boy.. Postgrad Med J, 65(764), 403-406.
- Response to growth hormone-releasing hormone as evidence of hypothalamic defect in optic nerve hypoplasia.. Acta Paediatr Scand, 78(3), 436-439.
- Growth hormone response to overnight growth hormone-releasing hormone infusion and oral pyridostigmine in children with short stature.. Acta Paediatr Scand Suppl, 349, 114-116.
- Growth-Hormone profiles in GH-deficient children on and off twice daily SC GHRH Therapy and during a SC infusion of GHRH. Pediatric Research, 24.
- Children with idiopathic short stature show a greater response to GHRH than insulin hypoglycemia - Response to GHRH (1-29)NH2 in 16 normal subjects and 55 children with short stature. Pediatric Research, 23.
- GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.. Clin Endocrinol (Oxf), 27(6), 727-733.
- Stilboestrol pretreatment of children with short stature does not affect the growth hormone response to growth hormone-releasing hormone.. Clin Endocrinol (Oxf), 27(2), 155-161.
- 5 Patients with Optic-Nerve Hypoplasia - CT Scan Apperances and Response to an Acute Bolus and Treatment with Growth Hormone-Releasing Hormone. Journal of Endocrinology, 112.
- Dopaminergic and Cholinergic Influences on the Growth-Hormone Response to Growth Hormone-Releasing Hormone in Man. Psychoneuroendocrinology, 45.
- Treatment of Growth-Hormone Deficiency with Growth-Hormone Releasing Hormone. Lancet, 1.
- Growth hormone-releasing hormone: studies in normal subjects and patients with disorders of growth hormone secretion.. Pediatrician, 14(3), 138-145.
- GROWTH HORMONE PRETREATMENT IN MAN BLOCKS THE RESPONSE TO GROWTH HORMONE‐RELEASING HORMONE; EVIDENCE FOR A DIRECT EFFECT OF GROWTH HORMONE. Clinical Endocrinology, 26(1), 117-123.
- Growth hormone releasing hormone in the assessment and long-term treatment of growth-hormone deficiency. Acta Paediatrica Scandinavica, 76(SUPPL. 331), 42-47.
- Enhancing Hypothalamic-Lesions Shown on High-Resolution Computerised-Tomography in Patients with Idiopathic Hypopituitarism. Pediatric Research, 20.
- Treatment of GH-Deficient Children with Twice Daily Subcutaneous GHRH(1-29)NH2. Pediatric Research, 20.
- Growth Hormone-Releasing Hormone-Treatment of of Growth-Hormone Deficient Children. Wounds: a compendium of clinical research and practice, 34.
- The Effects of Stilbestrol Pretreatment on the GH Response to Insulin Hypoglycemia and GHRH - Evidence for a Hypothalamic Site of Action. Journal of Endocrinology, 108.
- Cranial irradiation for cerebral and nasopharyngeal tumours in children: Evidence for the production of a hypothalamic defect in growth hormone release. Journal of Endocrinology, 108(1), 25-29.
- DEPOT‐BROMOCRIPTINE TREATMENT FOR PROLACTINOMAS AND ACROMEGALY. Clinical Endocrinology, 24(2), 231-238.
- THE RELATIONSHIP BETWEEN SERUM PROLACTIN AND IMMUNOCYTOCHEMICAL STAINING FOR PROLACTIN IN PATIENTS WITH PITUITARY MACROADENOMAS. Clinical Endocrinology, 23(3), 227-235.
- THE EFFECT OF DOPAMINE AGONIST THERAPY ON LARGE FUNCTIONLESS PITUITARY TUMOURS. Clinical Endocrinology, 22(5), 679-686.
- Alteration of Pituitary-Thyroid Function in Patients with Chronic Renal Failure Treated by Haemodialysis or Continuous Ambulatory Peritoneal Dialysis. Annals of Clinical Biochemistry, 22(2), 156-160.
- The Use of Growth Hormone-Releasing Hormone in the Diagnosis and Treatment of Short Stature. Hormone Research, 22(1-2), 52-57.
- Bilateral spontaneous pneumothorax in sarcoidosis. Postgrad Med J 1983;59:34 35..
- Measurement of thyroid hormone in labradors. Veterinary Record 1982 111, 329.
- Improved biochemical control with modified-release hydrocortisone overturns the impaired fludrocortisone effect in salt-wasting CAH patients. Endocrine Abstracts.
- Fertility in congenital adrenal hyperplasia (CAH) patients on modified release hydrocortisone capsules (MRHC, Efmody). Endocrine Abstracts.
- Adrenal insufficiency. Nature Reviews Disease Primers, 7(1).
- Surgical Practice in Girls with Congenital Adrenal Hyperplasia: An International Registry Study. Sexual Development, 1-7.
- First in man study of oral native testosterone in hypogonadal men shows physiological testosterone levels in fed and fasted state. Endocrine Abstracts.
- Rabbits are a suitable animal model for the pre-clinical development of growth hormone agonists and antagonists. Experimental and Clinical Endocrinology & Diabetes, 122(03).
- Endocrine and cardiac paracrine actions of insulin-like growth factor-I during thyroid dysfunction in the rat: is IGF-I implicated in the mechanism of heart weight/body weight change during abnormal thyroid function. J Mol Endocrinol 1993:10;313-323..
- Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin like growth factor 1.. Clinical Endocrinology 1991; 35:47 54..
Chapters
- Steroid Replacement in Adrenal Insufficiency, Encyclopedia of Endocrine Diseases (pp. 172-184). Elsevier
- Contributing Authors, Growth Hormone Secretagogues (pp. ix-xiv). Elsevier
- Growth Hormone Secretagogues in Catabolic Illness, Growth Hormone Secretagogues (pp. 237-246). Elsevier
- Long-Acting Growth Hormone Analogues In Ho E (Ed.), Growth Hormone Related Diseases and Therapy (pp. 361-373).
Conference proceedings papers
- Long-Term Cardiometabolic Morbidity in Young Adults with Classic 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. HORMONE RESEARCH IN PAEDIATRICS, Vol. 94(SUPPL 1) (pp 69-70)
- Engineering transient production of recombinant proteins by mammalian cells using siRNA. JOURNAL OF BIOTECHNOLOGY, Vol. 150 (pp S86-S87)
- GH, IGF-I and binding proteins in altered nutritional states. INTERNATIONAL JOURNAL OF OBESITY, Vol. 24 (pp S92-S95)
- Truncated growth hormone receptor isoforms. ACTA PAEDIATRICA, Vol. 88 (pp 164-166)
- New growth hormone receptor exon 9 mutation causes genetic short stature. ACTA PAEDIATRICA, Vol. 88 (pp 168-172)
- The use of growth hormone and insulin-like growth factor-I in catabolic states. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, Vol. 10 (pp 131-136)
- CLINICAL-APPLICATIONS OF IGF-I. TWO DECADES OF EXPERIENCE IN GROWTH, Vol. 100 (pp 39-50)
- ALTERATION OF PITUITARY-THYROID FUNCTION IN PATIENTS TREATED WITH HEMODIALYSIS (HD) AND CHRONIC AMBULATORY PERITONEAL-DIALYSIS (CAPD). CLINICAL SCIENCE, Vol. 65(3) (pp P14-P14)
Patents
- Recombinant Protein Production. WO/2010/100437 Appl. 10 Sep 2010.
- Cytokine Variant Polypeptides. WO01/096565 Appl. 05 May 2010.
- Treatment of Adrenal Insufficiency. WO/2010/032006 Appl. 25 Mar 2010.
- GLP-1 FUSION POLYPEPTIDES. WO/2010/020767 Appl. 25 Feb 2010.
- INTERLEUKIN FUSION POLYPEPTIDES. WO/2010/020766 Appl. 25 Feb 2010.
- INSULIN FUSION POLYPEPTIDES. WO/2010/001134 Appl. 07 Jan 2010.
- THYROID STIMULATING HORMONE FUSION PROTEINS. WO/2009/115809 Appl. 24 Sep 2009.
- MODIFIED LINKERS. WO/2009/103965 Appl. 27 Aug 2009.
- PROLACTIN FUSION PROTEINS. WO/2009/077731 Appl. 25 Jun 2009.
- MODIFIED GROWTH HORMONE POLYPEPTIDES. WO/2009/047474 Appl. 16 Apr 2009.
- ERYTHROPOIETIN FUSION PROTEINS. WO/2009/019458 Appl. 12 Feb 2009.
- INSULIN-LIKE GROWTH FACTOR FUSION PROTEINS. WO/2009/019465 Appl. 12 Feb 2009.
- GRANULOCYTE COLONY STIMULATING FACTOR. WO/2009/019441 Appl. 12 Feb 2009.
- Leptin Fusion Protein. WO/2009/019427 Appl. 12 Feb 2009.
- Lipid Compositions Comprising Androgens. WO/2009/133352 Appl. 05 Nov 2009.
- GROWTH HORMONE FUSION PROTEINS. WO/2009/013461 Appl. 29 Jan 2009.
- Treatment of Inflammation. WO/2008/065386 Appl. 05 Jun 2008.
- GROWTH FACTOR. WO/2008/032059 Appl. 20 Mar 2008.
- T3/T4 Sustained Release. WO/2008/129303 Appl. 30 Oct 2008.
- Circular Permutations. WO/2007/128979 Appl. 15 Nov 2007.
- Rigid Linkers. WO/2006/010891 Appl. 02 Feb 2006.
- Depression Treatment. WO/2005/065692 Appl. 21 Jul 2005.
- Leptin antagonis 9F8. WO/2005/049655 Appl. 02 Jun 2005.
- CYTOKINE POLYPEPTIDES AND ANTIBODIES CONTAINING A SIGNAL SEQUENCE FOR THE ATTACHEMENT OF GLYCOSYLPHOSPHATIDYLINOSITOL. WO/2004/090135 Appl. 21 Oct 2004.
- GROWTH HORMONE FUSION PROTEIN. WO/2003/070765 Appl. 28 Aug 2003.
- Tandem Polypeptides. WO/2003/062276 Appl. 31 Jul 2003.
- CHIMERIC GLYCOSYLPHOSPHATIDYLINOSITOL CONTAINING PEPTIDES
CHIMERIC GLYCOSYLPHOSPHATIDYLINOSITOL CONTAINING PEPTIDES
CHIMERIC GLYCOSYLPHOSPHATIDYLINOSITOL CONTAINING PEPTIDES. WO/2003/034275 Appl. 24 Apr 2003.
- Growth hormone fusion proteins. 8,470,559 (USA). Appl. 01 Jan 1970.
- Home waking salivary cortisone to screen for adrenal insufficiency. NEJM Evidence, 2(2).
- Teaching activities
-
I lecture medical students in Endocrinology and supervise PhD and BMedSci students.
- Professional activities and memberships
-
Editorship
- Editorial Board Clinical Endocrinology 1996-2000
- Editor: Growth and Growth Factors 1986-2006
- Editorial Board: Journal of Endocrinological Investigation 2004-07
- Editorial Board: Journal of Clinical Endocrinology & Metabolism 2010-
Advisory Boards
- NICE appraisal of adult growth hormone replacement 2003-04
- Member of Lilly HYPOCCS International Advisory Board 1999-2007
Society for Endocrinology
- Society for Endocrinology Media Committee 2009=-2012
- SFE Nomination Committee 2010
- A Director of Bioscientifica (2006-2010), the company that supports the Society for Endocrinology and promotes endocrinology internationally.
- I chair the Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE 2002-2015) which is a national group undertaking major research in the management of patients with congenital adrenal hyperplasia. We completed a study of over 200 patients published in J Clin Endocrinol Metab 2010.
University Spin Out Companies
- Founder of Asterion Ltd.
- Founder of Diurnal Ltd.
National Committee Membership
- Council Member, Society for Endocrinology 1999-01
- Society for Endocrinology Clinical Subcommittee, Audit 1997-99, Program Organiser 2000-02
- Treasurer of the European Society of Endocrinology (2013-2015),
- The Growth Hormone Research Society Council (2011-2016).